ABCG2 and neuroblastoma: Susceptibility to ABCG2-driven efflux severely compromises the performance of different classes of chemotherapeutics, including topoisomerase I inhibitors of the camptothecin family clinically used as a first-line treatment for NB [11,12,13,14].